Abstract
We aimed to evaluate the efficacy and safety of long-term use of etanercept therapy in patients with spondyloarthropathy (SpA) and rheumatoid arthritis (RA) on hemodialysis (HD). Selected RA or SpA patients treated with etanercept under HD were retrospectively evaluated. Etanercept-related adverse events were closely recorded for all patients. At the follow-up, erythrocyte sedimentation rate and C-reactive protein levels were monitored. Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) for SpA patients and Disease Activity Score (DAS28) for RA patients were measured at every 3 or 6 months. In total five end-stage renal disease (ESRD) patients were enrolled to the study. The causes of ESRD in the study subjects were amyloidosis (n = 2), analgesic nephropathy (n = 2), and nephrolithiasis (n = 1). Three were diagnosed as SpA and two were RA. All patients used etanercept. The median age was 39 years (range 22–72 years). The median disease duration was 12 years (range 2–20 years). The median follow-up after etanercept therapy was 18 months (range 5–33 months). DAS28 score decreased after the treatment and did not increase during follow-up in RA patients. BASDAI score decreased after the treatment during follow-up in three patients with SpA. At the follow-up, only one patient was diagnosed with septic arthritis. As a result of our study, etanercept treatment in RA and SpA patients on HD seems to be safe, well tolerated, and effective in most of the patients. Above all, due to impaired host defense in patients with ESRD, enhanced risk of infections should be kept in mind during follow-up period and larger trials are needed to prove the safety of etanercept in HD patients.
Similar content being viewed by others
References
Morrow J, Nelson L, Watts R, Isenberg D (1999) Autoimmune rheumatic disease, 2nd edn. Oxford University Press, Oxford, pp 104–146
Braun J, Bollow M, Remlinger G et al (1998) Prevalence of spondylarthropathies in HLA-B27 positive and negative blood donors. Arthritis Rheum 41:58–67
Tuglular S, Yalcinkaya F, Paydas S et al (2002) A retrospective analysis for aetiology and clinical findings of 287 secondary amyloidosis cases in Turkey. Nephrol Dial Transplant 17:2003–2005
Swarup A, Sachdeva N, Schumacher HR Jr (2004) Dosing of antirheumatic drugs in renal disease and dialysis. J Clin Rheumatol 10:190–204
Boey O, Van Hooland S, Woestenburg A, Van der Niepen P, Verbeelen D (2006) Methotrexate should not be used for patients with end-stage kidney disease. Acta Clin Belg 61:166–169
Hammoudeh M (2006) Infliximab treatment in a patient with rheumatoid arthritis on haemodialysis. Rheumatology 45:357–359
Kobak S (2010) Efficacy and safety of adalimumab in a patient with ankylosing spondylitis on peritoneal dialysis. Rheumatol Int. doi:10.1007/s00296-010-1457-7
Marocchi E, Spadaro A, Giannakakis K, Priori R, Valesini G (2010) Infliximab in a patient with ankylosing spondylitis and secondary IgA nephropathy requiring haemodialysis. Clin Exp Rheumatol 28:440
Don BR, Spin G, Nestorov I, Hutmacher M, Rose A, Kaysen GA (2005) The pharmacokinetics of etanercept in patients with end-stage renal disease on haemodialysis. J Pharm Pharmacol 57:1407–1413
Don BR, Kim K, Li J, Dwyer T, Alexander F, Kaysen GA (2010) The effect of etanercept on suppression of the systemic inflammatory response in chronic hemodialysis patients. Clin Nephrol 73:431–438
Fernández-Nebro A, Tomero E, Ortiz-Santamaría V et al (2005) Treatment of rheumatic inflammatory disease in 25 patients with secondary amyloidosis using tumor necrosis factor alpha antagonists. Am J Med 118:552–556
Cassano N, Vena GA (2008) Etanercept treatment in a hemodialysis patient with severe cyclosporine-resistant psoriasis and hepatitis C virus infection. Int J Dermatol 47:980–981
Disclosures
None.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Senel, S., Kisacik, B., Ugan, Y. et al. The efficacy and safety of etanercept in patients with rheumatoid arthritis and spondyloarthropathy on hemodialysis. Clin Rheumatol 30, 1369–1372 (2011). https://doi.org/10.1007/s10067-011-1782-6
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10067-011-1782-6